This media contains content some readers may find distressing or offensive. Viewer discretion is advised.
Click to display

Stephen Welstead/Getty Images

By Suzanne Blake
Reporter
0
Share
Newsweek is a Trust Project member
See more of our trusted coverage when you search.Prefer Newsweek on Googleto see more of our trusted coverage when you search.
A new daily pill being developed by veterinary scientists could help senior dogs live longer.
The treatment, which is still under regulatory review, is designed to slow the biological aging process in dogs and may become the first FDA‑approved drug to explicitly extend a pet’s lifespan, according to early testing from San Francisco-based biotech company Loyal.
Why It Matters
For millions of dog owners, aging often brings chronic illness, declining mobility, and difficult end‑of‑life decisions. A pill designed to slow aging itself, rather than treat individual diseases, could represent a fundamental shift in how veterinarians approach senior pet care.
Read More on Science
The drug could be especially significant for medium- and large-breed dogs, which typically live shorter lives and experience faster biological aging linked to higher levels of the hormone IGF‑1. By targeting that process, researchers say the treatment may extend not just lifespan but also the number of healthy years lived.
This media contains content some readers may find distressing or offensive. Viewer discretion is advised.
Click to display

...
What To Know
The drug, known as LOY‑002, is being developed by Loyal and works as a beef‑flavored prescription pill intended for dogs aged 10 and older who weigh more than 14 pounds, Good.is reported.
Rather than treating a specific disease, LOY‑002 targets aging itself by interacting with insulin‑like growth factor 1 (IGF‑1), which is a hormone involved in growth and metabolism. While IGF‑1 helps puppies grow, higher levels of the hormone later in life are associated with faster cellular aging, especially in larger dog breeds.
By reducing the effects of IGF‑1, the pill aims to slow a dog’s biological clock, potentially lowering the risk of age‑related disease and extending overall lifespan while preserving quality of life.
“Anyone who has cared for a dog knows the pain of watching them grow older, slower, and less active as they age," Brennen McKenzie, Loyal's director of veterinary medicine, told Newsweek.
"As a veterinarian, I have a lot of tools for identifying and managing the specific health problems that occur with aging like osteoarthritis and cancer. But we also need preventive tools to slow down the decline caused by aging and delay the onset of those problems. That’s where therapies like the ones Loyal is developing come in.
The drug may be particularly beneficial for medium- and large-breed dogs, which tend to live shorter lives than smaller dogs. Larger breeds generally have higher IGF‑1 activity, which scientists believe accelerates aging and increases vulnerability to organ dysfunction later in life.
Early testing suggests the pill could add years to a dog’s life, though exact gains vary and are still being studied.
LOY‑002 has already cleared two of the three major regulatory steps required by the U.S. Food and Drug Administration’s Center for Veterinary Medicine, according to Good.is.
Company executives said that securing FDA approval for a lifespan‑extending drug has been the company’s goal since its founding. If the final approval is granted, the pill could reach the market before the end of 2026.
As the global pet care market hit $261 billion last year, investor Anish Moonka wrote on X that the once-a-day pill giving pets an extra year of life could “easily become one of the best-selling veterinary drugs on the planet.”
“If LOY-002 gets approved, it would be the first drug the FDA has ever cleared to slow aging in any species, human or animal,” Moonka wrote.
What People Are Saying
Loyal Founder and CEO Celine Halioua said, as reported by Good.is: “Since founding Loyal six years ago, my goal has always been to get the first drug FDA approved for lifespan extension. This safety acceptance brings us very close to achieving that vision. We are well on our way to bringing the first dog longevity drugs to market.”
Investor Anish Moonka wrote on X regarding the new drug: “If you put a dog on a strict diet where it eats way less food, that dog tends to live about two years longer. Cancer and arthritis both show up later. The body just ages more slowly. LOY-002 gives the dog those exact benefits without actually eating less. The dog keeps its appetite and its weight; it just ages more slowly.”
What Happens Next
At this point, the pill is not yet available and should not be seen as a replacement for proven steps to support senior dogs, such as regular veterinary visits, exercise and nutrition.
However, the drug could represent a major shift in veterinary medicine: moving from treating age‑related conditions to addressing aging as a biological process.
Update 4/13/2026 9:22 a.m. ET: This article has been updated with comment from Brennen McKenzie.
View 0 Comments
Submit Correction
View Editorial & AI Guidelines